![Emma Tallantyre](https://profiles-cardiff.imgix.net/attachments/2615?w=200&h=200&auto=format&crop=faces&fit=crop&q=90")
Dr Emma Tallantyre
Senior Lecturer, Division of Psychological Medicine and Clinical Neurosciences
- Ar gael fel goruchwyliwr ôl-raddedig
Trosolwyg
Graddiais o Brifysgol Nottingham yn 2002. Cynhaliais fy hyfforddiant meddygol a niwrolegol ôl-raddedig yn Nottingham, Derby, Awstralia a De Cymru. Fel cymrawd ymchwil MRC, cwblheais PhD sy'n ymchwilio i ddelweddu (canolfan Syr Peter Mansfield MR) a niwropatholeg (Prifysgol Nottingham) o sglerosis ymledol (MS).
Rwyf wedi bod yn ymwneud â gofal clinigol pobl ag MS ers 2006. Cwblheais fy hyfforddiant clinigol yn 2015 a dod yn Uwch-ddarlithydd Clinigol mewn Niwroleg yn 2018, ac yn Ddarllenydd Clinigol yn 2022. Mae gen i gontract anrhydeddus i weithio yn Uned Niwroinflammatory Helen Durham yn Ysbyty Athrofaol Cymru. Fel rhan o'r rôl hon, rwy'n rhedeg clinigau MS a niwroleg gyffredinol wythnosol ac yn cyfrannu at ddatblygu gwasanaethau.
Mae fy niddordebau ymchwil presennol yn canolbwyntio ar ganlyniadau clefyd niwroinflammataidd. Rwy'n cymryd rhan mewn treialon clinigol sy'n ymchwilio i'r dulliau triniaeth gorau posibl mewn sglerosis ymledol. Mae gen i ddiddordeb mewn cyfuno data clinigol y byd go iawn â data biolegol a delweddu cysylltiedig i gryfhau rhagfynegiadau o ganlyniad a gwella dyluniad treialon. Mae gen i ddiddordeb hefyd mewn cynnwys cleifion a'r cyhoedd yn natblygiad astudiaethau ymchwil clinigol.
Cyhoeddiad
2025
- Griffiths, L. et al. 2025. Sterol imbalances and cholesterol-24-hydroxylase dysregulation is linked to the underlying progression of multiple sclerosis. Brain Pathology (10.1111/bpa.70001)
2024
- Arun, T. et al. 2024. Assessing the landscape and charting paths: UK neurology trainees' opinions on neuroinflammation subspecialty. Multiple Sclerosis and Related Disorders 92, article number: 106144. (10.1016/j.msard.2024.106144)
- Androdias, G. et al. 2024. De-escalating and discontinuing disease-modifying therapies in multiple sclerosis. Brain (10.1093/brain/awae409)
- Coerver, E. et al. 2024. The recurrence of disease activity after ocrelizumab discontinuation in multiple sclerosis. Multiple Sclerosis and Related Disorders 91, article number: 105900. (10.1016/j.msard.2024.105900)
- Nicholas, R. et al. 2024. Algorithmic approach to finding people with multiple sclerosis using routine healthcare data in Wales. Journal of Neurology, Neurosurgery & Psychiatry 96(11), pp. 1032-1035. (10.1136/jnnp-2024-333532)
- Gelissen, L. M. et al. 2024. Subcutaneous administration of natalizumab can lead to lower drug concentrations compared to intravenous administration. Multiple Sclerosis and Related Disorders 90, article number: 105796. (10.1016/j.msard.2024.105796)
- Roos, I. et al. 2024. Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal 30(9), pp. 1163-1175. (10.1177/13524585241267211)
- Tallantyre, E. C. et al. 2024. Real world persistence of multiple sclerosis disease modifying therapies. European Journal of Neurology 31(7), article number: e16289. (10.1111/ene.16289)
- De Dios perez, B. et al. 2024. The Impact of Covid-19 on the employment of people with multiple sclerosis: A multi-methods study. International Journal of MS Care 26(Q3), pp. 174-186. (10.7224/1537-2073.2023-049)
- Uzochukwu, E. C. et al. 2024. Modelling disease progression of Multiple Sclerosis in a South Wales cohort. Neuroepidemiology 58(3), pp. 218-226. (10.1159/000536427)
- Nasir, M. et al. 2024. Impact of rituximab treatment regime on time to relapse in aquaporin-4 antibody positive neuromyelitis optica spectrum disorder. Multiple Sclerosis and Related Disorders 85, article number: 105528. (10.1016/j.msard.2024.105528)
- Kreft, K. L. et al. 2024. Relevance of multiple sclerosis severity genotype in predicting disease course: A real-world cohort. Annals of Neurology 95(3), pp. 459-470. (10.1002/ana.26831)
- Kodosaki, E. et al. 2024. Combination protein biomarkers predict multiple sclerosis diagnosis and outcomes. Journal of Neuroinflammation 21(1), article number: 52. (10.1186/s12974-024-03036-4)
2023
- Papathanasiou, A. et al. 2023. Real world annualized relapse rates from contemporary multiple sclerosis clinics in the UK: A retrospective multicentre cohort study. Neurological Sciences 44, pp. 3629-3635. (10.1007/s10072-023-06838-1)
- Zaloum, S. et al. 2023. Risk of COVID-19 in people with multiple sclerosis who are seronegative following vaccination. Multiple Sclerosis Journal 29(8), pp. 979-989. (10.1177/13524585231185247)
- Htet, Z. M. and Tallantyre, E. 2023. Optic neuritis and MOGAD. Journal of Neurology 270(6), pp. 3278–3279. (10.1007/s00415-023-11738-7)
- Jacobs, B. M. et al. 2023. The ADAMS project - a genetic Association study in individuals from Diverse Ancestral backgrounds with Multiple Sclerosis based in the United Kingdom. BMJ Open 13, article number: e071656. (10.1136/bmjopen-2023-071656)
- Morgan, A., Tallantyre, E. and Ontaneda, D. 2023. The benefits and risks of escalation versus early highly effective treatment in patients with multiple sclerosis. Expert Review of Neurotherapeutics 23(5), pp. 433-444. (10.1080/14737175.2023.2208347)
- Harding, K. E. et al. 2023. Contemporary study of multiple sclerosis disability in South East Wales. Journal of Neurology, Neurosurgery and Psychiatry 94(4), pp. 272-279. (10.1136/jnnp-2022-330013)
- Garjani, A. et al. 2023. Decentralised clinical trials in multiple sclerosis research. Multiple Sclerosis Journal 29(3), pp. 317-325. (10.1177/13524585221100401)
2022
- Beesley, R. et al. 2022. Multiple sclerosis and COVID-19: Assessing risk perception, patient behaviours and access to disease-modifying therapies. Multiple Sclerosis and Related Disorders 68, article number: 104121. (10.1016/j.msard.2022.104121)
- Cauchi, M. et al. 2022. Multiple Sclerosis and the risk of infection: Association of British Neurologists consensus guideline. Practical Neurology 22(5), pp. 344-357. (10.1136/practneurol-2022-003370)
- Tallantyre, E. C. et al. 2022. Response to COVID-19 booster vaccinations in seronegative people with multiple sclerosis.. Multiple Sclerosis and Related Disorders 64, article number: 103937. (10.1016/j.msard.2022.103937)
- Tallantyre, E. C. 2022. Long-term treatment with anti-CD20 monoclonal antibodies is untenable because of risk ? No. Multiple Sclerosis Journal 28(8), pp. 1175-1177. (10.1177/13524585221091404)
- Garjani, A. et al. 2022. Mental health of people with multiple sclerosis during the COVID-19 outbreak: a prospective cohort and cross-sectional case-control study of the UK MS Register. Multiple Sclerosis Journal 28(7), pp. 1060-1071. (10.1177/13524585211020435)
- Topcu, G. et al. 2022. Neuropsychological evaluation and rehabilitation in multiple sclerosis (NEuRoMS): Protocol for a mixed-methods, multi-centre feasibility randomised controlled trial. Pilot and Feasibility Studies 8, article number: 123. (10.1186/s40814-022-01073-5)
- Allman, M., Tallantyre, E. and Robertson, N. P. 2022. Response to SARS-CoV-2 vaccination in multiple sclerosis patients on disease modifying therapies. Journal of Neurology 269(4), pp. 2259-2261. (10.1007/s00415-022-11053-7)
- Wood, C. H., Robertson, N., Min Htet, Z. and Tallantyre, E. 2022. Incidence of persistent lymphopenia in people with multiple sclerosis on dimethyl fumarate. Multiple Sclerosis and Related Disorders 58, article number: 103492. (10.1016/j.msard.2022.103492)
- Tallantyre, E. et al. 2022. COVID-19 vaccine response in people with multiple sclerosis. Annals of Neurology 91(1), pp. 89-100. (10.1002/ana.26251)
- Busse, M. et al. 2022. A web-based life-style, exercise and activity intervention for people with progressive multiple sclerosis results of a single-arm feasibility study. Multiple Sclerosis and Related Disorders 57, article number: 103388. (10.1016/j.msard.2021.103388)
2021
- Middleton, R. M. et al. 2021. COVID-19 in Multiple Sclerosis: clinically reported outcomes from the UK Multiple Sclerosis Register. Multiple Sclerosis and Related Disorders 56, article number: 103317. (10.1016/j.msard.2021.103317)
- Fernandes, L., Allen, C. M., Williams, T., Tallantyre, E., Evangelou, N., Chataway, J. and Ford, H. L. 2021. The contemporary role of MRI in the monitoring and management of people with multiple sclerosis in the UK. Multiple Sclerosis and Related Disorders 55, article number: 103190. (10.1016/j.msard.2021.103190)
- Chamberland, M., Winter, M., Brice, T. A. W., Jones, D. K. and Tallantyre, E. C. 2021. Beyond lesion-load: tractometry-based metrics for characterizing white matter lesions within fibre pathways. Presented at: MICCAI 2020 International Workshop on Computational Diffusion MRI (CDMRI 2020), Virtual, 8 October 2020 Presented at Gyori, N. et al. eds.Computational Diffusion MRI: International MICCAI Workshop, Lima, Peru, October 2020. Mathematics and Visualization pp. 227-237., (10.1007/978-3-030-73018-5_18)
- Winter, M., Tallantyre, E. C., Brice, T. A. W., Robertson, N. P., Jones, D. K. and Chamberland, M. 2021. Tract-specific MRI measures explain learning and recall differences in multiple sclerosis. Brain Communications 3(2), article number: fcab065. (10.1093/braincomms/fcab065)
- Garjani, A. et al. 2021. COVID-19 is associated with new symptoms of multiple sclerosis that are prevented by disease modifying therapies. Multiple Sclerosis and Related Disorders 52, article number: 102939. (10.1016/j.msard.2021.102939)
- Hares, K. et al. 2021. KIF5A and the contribution of susceptibility genotypes as a predictive biomarker for multiple sclerosis. Journal of Neurology 268, pp. 2175-2184. (10.1007/s00415-020-10373-w)
- MacIver, C. L., Ebden, S. and Tallantyre, E. C. 2021. MRI: how to understand it. Practical Neurology 21(3), pp. 216-224. (10.1136/practneurol-2020-002905)
- Lipp, I. et al. 2021. Predictors of training-related improvement in visuomotor performance in patients with multiple sclerosis: a behavioural and MRI study. Multiple Sclerosis 7(7), pp. 1088-1101. (10.1177/1352458520943788)
- Latchem-Hastings, J. et al. 2021. Lifestyle, exercise and activity package for people living with progressive multiple sclerosis (LEAP-MS): protocol for a single-arm feasibility study. Pilot and Feasibility Studies 7, article number: 111. (10.1186/s40814-021-00852-w)
- Tallantyre, E., Evans, N., Parry-Jones, J., Morgan, M., Jones, C. and Ingram, W. 2021. Neurological updates: neurological complications of CAR-T therapy. Journal of Neurology 268, pp. 1544-1554. (10.1007/s00415-020-10237-3)
- Busse, M. et al. 2021. A web-based physical activity intervention for people with progressive Multiple Sclerosis: application of consensus-based intervention development guidance. BMJ Open 11(3), article number: e045378. (10.1136/bmjopen-2020-045378)
- Evangelou, N. et al. 2021. Self-diagnosed COVID-19 in people with multiple sclerosis: a community-based cohort of the UK MS Register. Journal of Neurology, Neurosurgery and Psychiatry 92, pp. 107-109. (10.1136/jnnp-2020-324449)
- Allen-Philbey, K. et al. 2021. Subcutaneous cladribine to treat multiple sclerosis: Experience in 208 patients. Therapeutic Advances in Neurological Disorders 14, pp. 1-16. (10.1177/17562864211057661)
2020
- Zelek, W. M. et al. 2020. Cerebrospinal fluid complement system biomarkers in demyelinating disease. Multiple Sclerosis 26(14), pp. 1929-1937. (10.1177/1352458519887905)
- Anderson, V. et al. 2020. Serum neurofilament-light concentration and real-world outcome in MS. Journal of the Neurological Sciences 417, article number: 117079. (10.1016/j.jns.2020.117079)
- Ontaneda, D. et al. 2020. Determining the effectiveness of early intensive versus escalation approaches for the treatment of relapsing-remitting multiple sclerosis: The DELIVER-MS study protocol. Contemporary Clinical Trials 95 (10.1016/j.cct.2020.106009)
- Saxena, G. et al. 2020. Detecting and predicting neutralization of alemtuzumab responses in multiple sclerosis. Neurology, Neuroimmunology and Neuroinflammation 7(4), article number: e767. (10.1212/NXI.0000000000000767)
- Tallantyre, E., Castle, D., Karamura, P., Brice, T., Joseph, F., Harding, K. and Robertson, N. 2020. Eligibility and implementation of disease-modifying therapy for primary progressive multiple sclerosis in a UK cohort. Multiple Sclerosis and Related Disorders 42, article number: 102056. (10.1016/j.msard.2020.102056)
- Tallantyre, E. et al. 2020. Achieving effective patient and public involvement in international clinical trials in neurology. Neurology 10(3), pp. 265-272. (10.1212/CPJ.0000000000000739)
- Lipp, I. et al. 2020. Tractography in the presence of multiple sclerosis lesions. NeuroImage 209, article number: 116471. (10.1016/j.neuroimage.2019.116471)
- Allen, C. M., Feng, J. J., Willis, M. D., McGinley, M., Ontaneda, D., Tallantyre, E. C. and Evangelou, N. 2020. Clinical observation during alemtuzumab administration. Multiple Sclerosis and Related Disorders 37, article number: 101412. (10.1016/j.msard.2019.101412)
2019
- Davda, N., Tallantyre, E. and Robertson, N. P. 2019. Early MRI predictors of prognosis in multiple sclerosis. Journal of Neurology 266(12), pp. 3171-3173. (10.1007/s00415-019-09589-2)
- Abdullah, A. A. N. and Tallantyre, E. 2019. HSV-2 radiculitis: An unusual presentation mere days after genital infection. Clinical Neurology and Neurosurgery 185, article number: 105429. (10.1016/j.clineuro.2019.105429)
- Ontaneda, D., Tallantyre, E., Kalincik, T., Planchon, S. M. and Evangelou, N. 2019. Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis. Lancet Neurology 18(10), pp. 973-980. (10.1016/S1474-4422(19)30151-6)
- Castle, D., Wynford-Thomas, R., Loveless, S., Bentley, E., Howell, O. W. and Tallantyre, E. C. 2019. Using biomarkers to predict clinical outcomes in multiple sclerosis. Practical Neurology 19(4), pp. 342-349. (10.1136/practneurol-2018-002000)
- Lipp, I. et al. 2019. Comparing MRI metrics to quantify white matter microstructural damage in multiple sclerosis. Human Brain Mapping 40(10), pp. 2917-2932. (10.1002/hbm.24568)
- Harding, K. et al. 2019. Clinical outcomes of escalation vs early intensive disease-modifying therapy in patients with multiple sclerosis. JAMA Neurology 76(5), pp. 536-541. (10.1001/jamaneurol.2018.4905)
- Whittam, D. H. et al. 2019. Rituximab in neurological disease: principles, evidence and practice. Practical Neurology 19(1), pp. 5-10. (10.1136/practneurol-2018-001899)
2018
- Robertson, J. and Tallantyre, E. 2018. Nerve sheath tumours. Journal of Neurology 265(12), pp. 3034-3035. (10.1007/s00415-018-9098-y)
- Tallantyre, E. C., Robertson, N. P. and Jolles, S. 2018. Secondary antibody deficiency in neurology. Current Opinion in Allergy and Clinical Immunology 18(6), pp. 481-488. (10.1097/ACI.0000000000000485)
- Beesley, R. et al. 2018. Impact of the 2017 revisions to McDonald criteria on the diagnosis of Multiple Sclerosis. Multiple Sclerosis 24(13), pp. 1786-1787. (10.1177/1352458518778007)
- Harding, K. et al. 2018. A contemporary study of mortality in the multiple sclerosis population of south east Wales. Multiple Sclerosis and Related Disorders 25, pp. 186-191. (10.1016/j.msard.2018.08.001)
- Tallantyre, E. C. et al. 2018. How common is truly benign MS in a UK population?. Journal of Neurology, Neurosurgery and Psychiatry 90, pp. 522-528. (10.1136/jnnp-2018-318802)
- Alsaeed, M. et al. 2018. Multiple sclerosis: long-term outcomes in ethnic minorities. analysis of a UK population-based registry. European Journal of Neurology 25(4), pp. 701-704. (10.1111/ene.13571)
- Tallantyre, E., Whittam, D. H., Jolles, S., Paling, D., Constantinescu, C., Robertson, N. and Jacob, A. 2018. Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation. Journal of Neurology 265(5), pp. 1115-1122. (10.1007/s00415-018-8812-0)
2017
- Willis, M. et al. 2017. An observational study of alemtuzumab following fingolimod for multiple sclerosis. Neuroimmunology and Neuroinflammation 4(2), article number: E320. (10.1212/NXI.0000000000000320)
2016
- Tallantyre, E. C. and Robertson, N. P. 2016. Continuous evolution of magnetic resonance imaging in multiple sclerosis. Journal of Neurology 263(4), pp. 835-837. (10.1007/s00415-016-8099-y)
- Tallantyre, E. C., Wardle, M. and Robertson, N. 2016. How to run a multiple sclerosis relapse clinic. Practical Neurology 16(1), pp. 62-69. (10.1136/practneurol-2015-001214)
2015
- Thomas, R. H. et al. 2015. Why neurology? The career choices of current UK neurology trainees [Conference Abstract]. Journal of Neurology, Neurosurgery & Psychiatry 86(11), pp. e4., article number: 42. (10.1136/jnnp-2015-312379.42)
- Williams, O., Tallantyre, E. C. and Robertson, N. 2015. Traumatic brain injury: pathophysiology, clinical outcome and treatment. Journal of Neurology 262(5), pp. 1394-1396. (10.1007/s00415-015-7741-4)
- Tallantyre, E., Causon, E. G., Harding, K., Pickersgill, T. P. and Robertson, N. 2015. The aetiology of acute neurological decline in multiple sclerosis: Experience from an open-access clinic. Multiple Sclerosis Journal 21(1), pp. 67-75. (10.1177/1352458514538333)
- Tallantyre, E. C. and Robertson, N. 2015. Acute stroke management. Journal of Neurology 262(1), pp. 239-242. (10.1007/s00415-014-7607-1)
2013
- Tallantyre, E. C. and Robertson, N. 2013. Autism and intellectual disability. Journal of Neurology 260(3), pp. 936-939. (10.1007/s00415-013-6861-y)
Articles
- Griffiths, L. et al. 2025. Sterol imbalances and cholesterol-24-hydroxylase dysregulation is linked to the underlying progression of multiple sclerosis. Brain Pathology (10.1111/bpa.70001)
- Arun, T. et al. 2024. Assessing the landscape and charting paths: UK neurology trainees' opinions on neuroinflammation subspecialty. Multiple Sclerosis and Related Disorders 92, article number: 106144. (10.1016/j.msard.2024.106144)
- Androdias, G. et al. 2024. De-escalating and discontinuing disease-modifying therapies in multiple sclerosis. Brain (10.1093/brain/awae409)
- Coerver, E. et al. 2024. The recurrence of disease activity after ocrelizumab discontinuation in multiple sclerosis. Multiple Sclerosis and Related Disorders 91, article number: 105900. (10.1016/j.msard.2024.105900)
- Nicholas, R. et al. 2024. Algorithmic approach to finding people with multiple sclerosis using routine healthcare data in Wales. Journal of Neurology, Neurosurgery & Psychiatry 96(11), pp. 1032-1035. (10.1136/jnnp-2024-333532)
- Gelissen, L. M. et al. 2024. Subcutaneous administration of natalizumab can lead to lower drug concentrations compared to intravenous administration. Multiple Sclerosis and Related Disorders 90, article number: 105796. (10.1016/j.msard.2024.105796)
- Roos, I. et al. 2024. Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal 30(9), pp. 1163-1175. (10.1177/13524585241267211)
- Tallantyre, E. C. et al. 2024. Real world persistence of multiple sclerosis disease modifying therapies. European Journal of Neurology 31(7), article number: e16289. (10.1111/ene.16289)
- De Dios perez, B. et al. 2024. The Impact of Covid-19 on the employment of people with multiple sclerosis: A multi-methods study. International Journal of MS Care 26(Q3), pp. 174-186. (10.7224/1537-2073.2023-049)
- Uzochukwu, E. C. et al. 2024. Modelling disease progression of Multiple Sclerosis in a South Wales cohort. Neuroepidemiology 58(3), pp. 218-226. (10.1159/000536427)
- Nasir, M. et al. 2024. Impact of rituximab treatment regime on time to relapse in aquaporin-4 antibody positive neuromyelitis optica spectrum disorder. Multiple Sclerosis and Related Disorders 85, article number: 105528. (10.1016/j.msard.2024.105528)
- Kreft, K. L. et al. 2024. Relevance of multiple sclerosis severity genotype in predicting disease course: A real-world cohort. Annals of Neurology 95(3), pp. 459-470. (10.1002/ana.26831)
- Kodosaki, E. et al. 2024. Combination protein biomarkers predict multiple sclerosis diagnosis and outcomes. Journal of Neuroinflammation 21(1), article number: 52. (10.1186/s12974-024-03036-4)
- Papathanasiou, A. et al. 2023. Real world annualized relapse rates from contemporary multiple sclerosis clinics in the UK: A retrospective multicentre cohort study. Neurological Sciences 44, pp. 3629-3635. (10.1007/s10072-023-06838-1)
- Zaloum, S. et al. 2023. Risk of COVID-19 in people with multiple sclerosis who are seronegative following vaccination. Multiple Sclerosis Journal 29(8), pp. 979-989. (10.1177/13524585231185247)
- Htet, Z. M. and Tallantyre, E. 2023. Optic neuritis and MOGAD. Journal of Neurology 270(6), pp. 3278–3279. (10.1007/s00415-023-11738-7)
- Jacobs, B. M. et al. 2023. The ADAMS project - a genetic Association study in individuals from Diverse Ancestral backgrounds with Multiple Sclerosis based in the United Kingdom. BMJ Open 13, article number: e071656. (10.1136/bmjopen-2023-071656)
- Morgan, A., Tallantyre, E. and Ontaneda, D. 2023. The benefits and risks of escalation versus early highly effective treatment in patients with multiple sclerosis. Expert Review of Neurotherapeutics 23(5), pp. 433-444. (10.1080/14737175.2023.2208347)
- Harding, K. E. et al. 2023. Contemporary study of multiple sclerosis disability in South East Wales. Journal of Neurology, Neurosurgery and Psychiatry 94(4), pp. 272-279. (10.1136/jnnp-2022-330013)
- Garjani, A. et al. 2023. Decentralised clinical trials in multiple sclerosis research. Multiple Sclerosis Journal 29(3), pp. 317-325. (10.1177/13524585221100401)
- Beesley, R. et al. 2022. Multiple sclerosis and COVID-19: Assessing risk perception, patient behaviours and access to disease-modifying therapies. Multiple Sclerosis and Related Disorders 68, article number: 104121. (10.1016/j.msard.2022.104121)
- Cauchi, M. et al. 2022. Multiple Sclerosis and the risk of infection: Association of British Neurologists consensus guideline. Practical Neurology 22(5), pp. 344-357. (10.1136/practneurol-2022-003370)
- Tallantyre, E. C. et al. 2022. Response to COVID-19 booster vaccinations in seronegative people with multiple sclerosis.. Multiple Sclerosis and Related Disorders 64, article number: 103937. (10.1016/j.msard.2022.103937)
- Tallantyre, E. C. 2022. Long-term treatment with anti-CD20 monoclonal antibodies is untenable because of risk ? No. Multiple Sclerosis Journal 28(8), pp. 1175-1177. (10.1177/13524585221091404)
- Garjani, A. et al. 2022. Mental health of people with multiple sclerosis during the COVID-19 outbreak: a prospective cohort and cross-sectional case-control study of the UK MS Register. Multiple Sclerosis Journal 28(7), pp. 1060-1071. (10.1177/13524585211020435)
- Topcu, G. et al. 2022. Neuropsychological evaluation and rehabilitation in multiple sclerosis (NEuRoMS): Protocol for a mixed-methods, multi-centre feasibility randomised controlled trial. Pilot and Feasibility Studies 8, article number: 123. (10.1186/s40814-022-01073-5)
- Allman, M., Tallantyre, E. and Robertson, N. P. 2022. Response to SARS-CoV-2 vaccination in multiple sclerosis patients on disease modifying therapies. Journal of Neurology 269(4), pp. 2259-2261. (10.1007/s00415-022-11053-7)
- Wood, C. H., Robertson, N., Min Htet, Z. and Tallantyre, E. 2022. Incidence of persistent lymphopenia in people with multiple sclerosis on dimethyl fumarate. Multiple Sclerosis and Related Disorders 58, article number: 103492. (10.1016/j.msard.2022.103492)
- Tallantyre, E. et al. 2022. COVID-19 vaccine response in people with multiple sclerosis. Annals of Neurology 91(1), pp. 89-100. (10.1002/ana.26251)
- Busse, M. et al. 2022. A web-based life-style, exercise and activity intervention for people with progressive multiple sclerosis results of a single-arm feasibility study. Multiple Sclerosis and Related Disorders 57, article number: 103388. (10.1016/j.msard.2021.103388)
- Middleton, R. M. et al. 2021. COVID-19 in Multiple Sclerosis: clinically reported outcomes from the UK Multiple Sclerosis Register. Multiple Sclerosis and Related Disorders 56, article number: 103317. (10.1016/j.msard.2021.103317)
- Fernandes, L., Allen, C. M., Williams, T., Tallantyre, E., Evangelou, N., Chataway, J. and Ford, H. L. 2021. The contemporary role of MRI in the monitoring and management of people with multiple sclerosis in the UK. Multiple Sclerosis and Related Disorders 55, article number: 103190. (10.1016/j.msard.2021.103190)
- Winter, M., Tallantyre, E. C., Brice, T. A. W., Robertson, N. P., Jones, D. K. and Chamberland, M. 2021. Tract-specific MRI measures explain learning and recall differences in multiple sclerosis. Brain Communications 3(2), article number: fcab065. (10.1093/braincomms/fcab065)
- Garjani, A. et al. 2021. COVID-19 is associated with new symptoms of multiple sclerosis that are prevented by disease modifying therapies. Multiple Sclerosis and Related Disorders 52, article number: 102939. (10.1016/j.msard.2021.102939)
- Hares, K. et al. 2021. KIF5A and the contribution of susceptibility genotypes as a predictive biomarker for multiple sclerosis. Journal of Neurology 268, pp. 2175-2184. (10.1007/s00415-020-10373-w)
- MacIver, C. L., Ebden, S. and Tallantyre, E. C. 2021. MRI: how to understand it. Practical Neurology 21(3), pp. 216-224. (10.1136/practneurol-2020-002905)
- Lipp, I. et al. 2021. Predictors of training-related improvement in visuomotor performance in patients with multiple sclerosis: a behavioural and MRI study. Multiple Sclerosis 7(7), pp. 1088-1101. (10.1177/1352458520943788)
- Latchem-Hastings, J. et al. 2021. Lifestyle, exercise and activity package for people living with progressive multiple sclerosis (LEAP-MS): protocol for a single-arm feasibility study. Pilot and Feasibility Studies 7, article number: 111. (10.1186/s40814-021-00852-w)
- Tallantyre, E., Evans, N., Parry-Jones, J., Morgan, M., Jones, C. and Ingram, W. 2021. Neurological updates: neurological complications of CAR-T therapy. Journal of Neurology 268, pp. 1544-1554. (10.1007/s00415-020-10237-3)
- Busse, M. et al. 2021. A web-based physical activity intervention for people with progressive Multiple Sclerosis: application of consensus-based intervention development guidance. BMJ Open 11(3), article number: e045378. (10.1136/bmjopen-2020-045378)
- Evangelou, N. et al. 2021. Self-diagnosed COVID-19 in people with multiple sclerosis: a community-based cohort of the UK MS Register. Journal of Neurology, Neurosurgery and Psychiatry 92, pp. 107-109. (10.1136/jnnp-2020-324449)
- Allen-Philbey, K. et al. 2021. Subcutaneous cladribine to treat multiple sclerosis: Experience in 208 patients. Therapeutic Advances in Neurological Disorders 14, pp. 1-16. (10.1177/17562864211057661)
- Zelek, W. M. et al. 2020. Cerebrospinal fluid complement system biomarkers in demyelinating disease. Multiple Sclerosis 26(14), pp. 1929-1937. (10.1177/1352458519887905)
- Anderson, V. et al. 2020. Serum neurofilament-light concentration and real-world outcome in MS. Journal of the Neurological Sciences 417, article number: 117079. (10.1016/j.jns.2020.117079)
- Ontaneda, D. et al. 2020. Determining the effectiveness of early intensive versus escalation approaches for the treatment of relapsing-remitting multiple sclerosis: The DELIVER-MS study protocol. Contemporary Clinical Trials 95 (10.1016/j.cct.2020.106009)
- Saxena, G. et al. 2020. Detecting and predicting neutralization of alemtuzumab responses in multiple sclerosis. Neurology, Neuroimmunology and Neuroinflammation 7(4), article number: e767. (10.1212/NXI.0000000000000767)
- Tallantyre, E., Castle, D., Karamura, P., Brice, T., Joseph, F., Harding, K. and Robertson, N. 2020. Eligibility and implementation of disease-modifying therapy for primary progressive multiple sclerosis in a UK cohort. Multiple Sclerosis and Related Disorders 42, article number: 102056. (10.1016/j.msard.2020.102056)
- Tallantyre, E. et al. 2020. Achieving effective patient and public involvement in international clinical trials in neurology. Neurology 10(3), pp. 265-272. (10.1212/CPJ.0000000000000739)
- Lipp, I. et al. 2020. Tractography in the presence of multiple sclerosis lesions. NeuroImage 209, article number: 116471. (10.1016/j.neuroimage.2019.116471)
- Allen, C. M., Feng, J. J., Willis, M. D., McGinley, M., Ontaneda, D., Tallantyre, E. C. and Evangelou, N. 2020. Clinical observation during alemtuzumab administration. Multiple Sclerosis and Related Disorders 37, article number: 101412. (10.1016/j.msard.2019.101412)
- Davda, N., Tallantyre, E. and Robertson, N. P. 2019. Early MRI predictors of prognosis in multiple sclerosis. Journal of Neurology 266(12), pp. 3171-3173. (10.1007/s00415-019-09589-2)
- Abdullah, A. A. N. and Tallantyre, E. 2019. HSV-2 radiculitis: An unusual presentation mere days after genital infection. Clinical Neurology and Neurosurgery 185, article number: 105429. (10.1016/j.clineuro.2019.105429)
- Ontaneda, D., Tallantyre, E., Kalincik, T., Planchon, S. M. and Evangelou, N. 2019. Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis. Lancet Neurology 18(10), pp. 973-980. (10.1016/S1474-4422(19)30151-6)
- Castle, D., Wynford-Thomas, R., Loveless, S., Bentley, E., Howell, O. W. and Tallantyre, E. C. 2019. Using biomarkers to predict clinical outcomes in multiple sclerosis. Practical Neurology 19(4), pp. 342-349. (10.1136/practneurol-2018-002000)
- Lipp, I. et al. 2019. Comparing MRI metrics to quantify white matter microstructural damage in multiple sclerosis. Human Brain Mapping 40(10), pp. 2917-2932. (10.1002/hbm.24568)
- Harding, K. et al. 2019. Clinical outcomes of escalation vs early intensive disease-modifying therapy in patients with multiple sclerosis. JAMA Neurology 76(5), pp. 536-541. (10.1001/jamaneurol.2018.4905)
- Whittam, D. H. et al. 2019. Rituximab in neurological disease: principles, evidence and practice. Practical Neurology 19(1), pp. 5-10. (10.1136/practneurol-2018-001899)
- Robertson, J. and Tallantyre, E. 2018. Nerve sheath tumours. Journal of Neurology 265(12), pp. 3034-3035. (10.1007/s00415-018-9098-y)
- Tallantyre, E. C., Robertson, N. P. and Jolles, S. 2018. Secondary antibody deficiency in neurology. Current Opinion in Allergy and Clinical Immunology 18(6), pp. 481-488. (10.1097/ACI.0000000000000485)
- Beesley, R. et al. 2018. Impact of the 2017 revisions to McDonald criteria on the diagnosis of Multiple Sclerosis. Multiple Sclerosis 24(13), pp. 1786-1787. (10.1177/1352458518778007)
- Harding, K. et al. 2018. A contemporary study of mortality in the multiple sclerosis population of south east Wales. Multiple Sclerosis and Related Disorders 25, pp. 186-191. (10.1016/j.msard.2018.08.001)
- Tallantyre, E. C. et al. 2018. How common is truly benign MS in a UK population?. Journal of Neurology, Neurosurgery and Psychiatry 90, pp. 522-528. (10.1136/jnnp-2018-318802)
- Alsaeed, M. et al. 2018. Multiple sclerosis: long-term outcomes in ethnic minorities. analysis of a UK population-based registry. European Journal of Neurology 25(4), pp. 701-704. (10.1111/ene.13571)
- Tallantyre, E., Whittam, D. H., Jolles, S., Paling, D., Constantinescu, C., Robertson, N. and Jacob, A. 2018. Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation. Journal of Neurology 265(5), pp. 1115-1122. (10.1007/s00415-018-8812-0)
- Willis, M. et al. 2017. An observational study of alemtuzumab following fingolimod for multiple sclerosis. Neuroimmunology and Neuroinflammation 4(2), article number: E320. (10.1212/NXI.0000000000000320)
- Tallantyre, E. C. and Robertson, N. P. 2016. Continuous evolution of magnetic resonance imaging in multiple sclerosis. Journal of Neurology 263(4), pp. 835-837. (10.1007/s00415-016-8099-y)
- Tallantyre, E. C., Wardle, M. and Robertson, N. 2016. How to run a multiple sclerosis relapse clinic. Practical Neurology 16(1), pp. 62-69. (10.1136/practneurol-2015-001214)
- Thomas, R. H. et al. 2015. Why neurology? The career choices of current UK neurology trainees [Conference Abstract]. Journal of Neurology, Neurosurgery & Psychiatry 86(11), pp. e4., article number: 42. (10.1136/jnnp-2015-312379.42)
- Williams, O., Tallantyre, E. C. and Robertson, N. 2015. Traumatic brain injury: pathophysiology, clinical outcome and treatment. Journal of Neurology 262(5), pp. 1394-1396. (10.1007/s00415-015-7741-4)
- Tallantyre, E., Causon, E. G., Harding, K., Pickersgill, T. P. and Robertson, N. 2015. The aetiology of acute neurological decline in multiple sclerosis: Experience from an open-access clinic. Multiple Sclerosis Journal 21(1), pp. 67-75. (10.1177/1352458514538333)
- Tallantyre, E. C. and Robertson, N. 2015. Acute stroke management. Journal of Neurology 262(1), pp. 239-242. (10.1007/s00415-014-7607-1)
- Tallantyre, E. C. and Robertson, N. 2013. Autism and intellectual disability. Journal of Neurology 260(3), pp. 936-939. (10.1007/s00415-013-6861-y)
Conferences
- Chamberland, M., Winter, M., Brice, T. A. W., Jones, D. K. and Tallantyre, E. C. 2021. Beyond lesion-load: tractometry-based metrics for characterizing white matter lesions within fibre pathways. Presented at: MICCAI 2020 International Workshop on Computational Diffusion MRI (CDMRI 2020), Virtual, 8 October 2020 Presented at Gyori, N. et al. eds.Computational Diffusion MRI: International MICCAI Workshop, Lima, Peru, October 2020. Mathematics and Visualization pp. 227-237., (10.1007/978-3-030-73018-5_18)
Ymchwil
Mae gen i brofiad o ddefnyddio delweddu strwythurol maes uchel i ddelweddu mater gwyn a phatholeg mater llwyd yn ymennydd pobl ag MS. Yn ystod fy PhD, cydberthynnais mewn canfyddiadau delweddu vivo MR gyda'r patholeg niwroddirywiol a welir yn ymennydd post mortem a chordiau asgwrn cefn y rhai sydd ag MS hirsefydlog.
Mae fy niddordebau ymchwil presennol yn canolbwyntio ar ganlyniadau clefyd niwroinflammataidd. Rwy'n cymryd rhan mewn treialon clinigol sy'n ymchwilio i'r dulliau triniaeth gorau posibl mewn sglerosis ymledol. Rwy'n cyfrannu at brosiect epidemiolegol sy'n rhedeg yn hir, gan gasglu data clinigol yn rhagolygol gan garfan o bobl â chlefydau niwroinflammatory gan gynnwys MS. Mae gen i ddiddordeb mewn cyfuno'r data clinigol byd go iawn hwn â data biolegol a delweddu cysylltiedig i gryfhau rhagfynegiadau o ganlyniad a gwella dyluniad treialon. Mae gen i ddiddordeb hefyd mewn cynnwys cleifion a'r cyhoedd yn natblygiad astudiaethau ymchwil clinigol.
Grantiau a Gwobrau
- Ferblanc. (Cyd-ymgeisydd) Biofarcwyr diagnostig a rhagfynegol mewn Neurosarcoidosis a Sglerosis Ymledol: Astudiaeth arfaethedig. £20,000. Ionawr 2023 - Rhagfyr 2023.
- Academi'r Gwyddorau Meddygol. (Cyd-ymgeisydd) Cynllun INSIPRE. £80,000. Chwefror 2023 - Chwefror 2025.
- Prifysgol Caerdydd, Gwobr Seilwaith Ymchwil. (Ymgeisydd arweiniol) Cais am Dadansoddwr Simoa HD. £228,807. 2021 - 2022.
- Prifysgol Caerdydd, Gwobr Seilwaith Ymchwil. (Cyd-ymgeisydd) Cais am Coil Amrywiaeth ar gyfer delweddu Sodiwm MR. £157,600. 2021 - 2022.
- Cymdeithas Feddygol Prydain. (Ymgeisydd Arweiniol). Ymatebion imiwnedd i frechu mewn pobl ag MS. £63,857. Awst 2021 - 2022.
- Gwobr Hyder mewn Cysyniad MRC. (Ymgeisydd arweiniol). Biofarcwyr diagnostig a rhagfynegol yn Multiple Sclerosis plasma: dull sgrinio cynhwysfawr. £48,671 (100% i Gaerdydd). Rhagfyr 2019 – Mehefin 2021. 1 awr yr wythnos.
- Gwobr Poblogaeth Cefnogaeth Strategol Sefydliadol Wellcome. (Ymgeisydd arweiniol). Modelu cyfoes o ganlyniadau Sglerosis Ymledol mewn poblogaeth yn Ne Cymru. (Prif ymgeisydd). £47,760 (derbyniwyd 100%). Medi 2019 – Rhagfyr 2021. 0.5 awr yr wythnos.
- Cymdeithas Sglerosis Ymledol Genedlaethol (UDA) a Chymdeithas MS y DU; Cais ar y cyd am arian ychwanegol. Biobanking in Treatment Approach Studies in Relapsing Remitting multiple Sclerosis. (Ymgeisydd Arweiniol ar safle is-gontract). £29,134 (100% i Gaerdydd). Ebrill 2019 – Rhagfyr 2022. 0.5 awr yr wythnos.
- Y Sefydliad Cenedlaethol ar gyfer Ymchwil Iechyd. PENDERFYNOL - DiagnosE gan ddefnyddio'r SIgn gwythiennau Canolog. Astudiaeth ragoriaeth ddiagnostig bosibl sy'n cymharu MRI T2* a phwnigo lumbar mewn cleifion sy'n cyflwyno Sglerosis Ymledol posibl. (Cyd-ymgeisydd). £349,461 [£27,250 i Gaerdydd]. Gorffennaf 2019 – Mehefin 2022. 0.5 awr yr wythnos.
- Ymddiriedolaeth Dowager Eleanor Peel (Prif ymgeisydd) Serwm Neuroffilaments mewn sglerosis ymledol. £9,936 (derbyniwyd 100%). Medi 2018 – Medi 2019.
- Sefydliad Ymchwil Canlyniad sy'n Canolbwyntio ar Gleifion (PCORI; cyd-ymgeisydd) 2017 - Pennu effeithiolrwydd dulliau dwys cynnar yn erbyn uwchgyfeirio ar gyfer trin sglerosis ymledol (DELIVER-MS) remitsing-remitting ymledol (DELIVER-MS) -£7.5m.
- MS Society 2017 (cyd-ymgeisydd) - Pecyn Bywyd, Ymarfer Corff a Gweithgareddau i Bobl sy'n byw gyda Sglerosis Ymledol Blaengar (MS-LEAP) - £293,000.
- Ymchwil Iechyd a Gofal Cymru - Gwobr Ymchwil Glinigol 2016 - £67,927
- Gwobr Cronfa Cymorth Strategol Sefydliadol Ymddiriedolaeth Wellcome (cyd-ymgeisydd) 2015 - £34,000
- Hyfforddiant Trawsnewid Hyfforddeion 2015 - £5,000
- Biogen Idec MS Cymrodoriaeth y Gofrestrfa Fyd-eang 2014 - £62,000
- Cymrodoriaeth Hyfforddiant Clinigol MRC, 2007 - £100,000
- Ymddiriedolaeth Feddygol Peele, Grant Ymchwil, 2006 - £5,000
Addysgu
Rwy'n cyfrannu at addysgu niwroleg Israddedig Meddygol C21. Rwy'n diwtor clinigol i fyfyrwyr 4oed sy'n cylchdroi trwy leoliadau Niwroleg ac rwyf hefyd wedi bod yn diwtor israddedig i grŵp o fyfyrwyr1af - 2il flwyddyn ers iddynt ddechrau ar y cwrs meddygol.
Rwy'n cynnal rhaglen reolaidd o brosiectau SSC3 a 4 blynedd yn ogystal â BSc prosiectau rhyng-gyfrifedig ar gyfer y cwrs meddygol israddedig. Rydym yn derbyn adborth da yn gyson gan ein myfyrwyr ac yn mwynhau'r rhyngweithio y maent yn ei gynnig i'r adran.
Rwy'n trefnu diwrnodau addysgu a hyfforddi ar gyfer hyfforddeion Arbenigedd Niwroleg ar draws y rhanbarth ar bynciau gan gynnwys Niwropatholeg, Niwroddelweddu a Niwro-oncoleg, gyda siaradwyr gwadd ac ystod o fformatau.
Rwy'n arholwr mewn arholiadau pratical ffurfiannol a chrynodol israddedig (OSCE / ISCE).
Bywgraffiad
Swyddi academaidd a chlinigol
|
Darllenydd Clinigol |
Prifysgol Caerdydd |
Awst 2022 - presennol |
|
Uwch Ddarlithydd Clinigol |
Prifysgol Caerdydd |
Mawrth 2018 - Awst 2022 |
|
Niwrolegydd Ymgynghorol |
Ysbyty Athrofaol Cymru |
Mawrth 2017 – Chwef 2018 |
|
Uwch Ddarlithydd Clinigol |
Prifysgol Caerdydd |
Mawrth 2016 – Chwef 2017 |
|
Cymrawd Ymchwil Ôl-CCT
SpR Niwroleg |
Ysbyty Athrofaol Cymru Deoniaeth Cymru |
Gorffennaf 2015 – Chwefror 2016
Awst 2012 – Gorffennaf 2015 |
|
SpR Niwroleg |
Deoniaeth Dwyrain Canolbarth Lloegr |
Awst 2009 – Awst 2012 |
Aelodaethau proffesiynol
- Aelod o Goleg Brenhinol y Meddygon
- Cymdeithas Niwroleg Prydain
- Trwydded General Medical Council i ymarfer
Pwyllgorau ac adolygu
Rwy'n adolygu llawysgrifau yn rheolaidd ar gyfer cyhoeddiad a adolygir gan gymheiriaid.
Rwy'n adolygydd ac rwyf wedi cyfweld am wobrau grant drwy Gymdeithas Niwroleg Prydain.
Rwyf hefyd wedi adolygu dyfarniadau grant i MRC ac MS Society.
Meysydd goruchwyliaeth
Mae gen i ddiddordeb mewn goruchwylio myfyrwyr PhD yn
Clefyd niwroinflammatory
Niwroddelweddu yn MS
